William Blair Reiterates “Outperform” Rating for Context Therapeutics (NASDAQ:CNTX)
Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a note issued to investors on Tuesday,RTT News reports. William Blair also issued estimates for Context Therapeutics’ Q1 2026 earnings at ($0.08) EPS and Q3 2026 earnings at ($0.08) EPS. Several other brokerages have […]
Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at William Blair in a note issued to investors on Tuesday,RTT News reports. William Blair also issued estimates for Context Therapeutics’ Q1 2026 earnings at ($0.08) EPS and Q3 2026 earnings at ($0.08) EPS. Several other brokerages have […]
